Skip to main content

Otonomy, Inc. (OTIC)

NASDAQ: OTIC · IEX Real-Time Price · USD
1.65 -0.10 (-5.71%)
Sep 20, 2021 2:38 PM EDT - Market open
Market Cap99.19M
Revenue (ttm)228,000
Net Income (ttm)-46.24M
Shares Out65.63M
EPS (ttm)-0.84
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume470,309
Open1.65
Previous Close1.75
Day's Range1.61 - 1.70
52-Week Range1.14 - 6.98
Beta1.99
AnalystsStrong Buy
Price Target5.63 (+241.2%)
Est. Earnings DateNov 3, 2021

About OTIC

Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone that has completed Phase III clinical trial for the treatment of Ménière's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed Phase I/II clinica...

IndustryPharmaceuticals
IPO DateAug 13, 2014
CEODavid Weber
Employees56
Stock ExchangeNASDAQ
Ticker SymbolOTIC
Full Company Profile

Financial Performance

In 2020, Otonomy's revenue was $273,000, a decrease of -54.50% compared to the previous year's $600,000. Losses were -$44.73 million, 0.13% more than in 2019.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for Otonomy stock is "Strong Buy." The 12-month stock price forecast is 5.63, which is an increase of 241.21% from the latest price.

Price Target
$5.63
(241.21% upside)
Analyst Consensus: Strong Buy

News

Otonomy to Participate in Two Upcoming Investor Conferences

SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that mana...

2 weeks ago - GlobeNewsWire

Otonomy Appoints Jill Broadfoot to Board of Directors

SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the appoin...

1 month ago - GlobeNewsWire

Otonomy (OTIC) Reports Q2 Loss, Lags Revenue Estimates

Otonomy (OTIC) delivered earnings and revenue surprises of -11.76% and -46.15%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Otonomy Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Conference call and webcast today at 4:30 p.m. ET

1 month ago - GlobeNewsWire

Otonomy to Report Second Quarter 2021 Financial Results and Provide Corporate Update

SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will re...

1 month ago - GlobeNewsWire

Will Otonomy (OTIC) Report Negative Q2 Earnings? What You Should Know

Otonomy (OTIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Otonomy Initiates Expansion of Phase 1/2 Clinical Trial for OTO-413 in Hearing Loss

SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initia...

3 months ago - GlobeNewsWire

Otonomy's OTO-825 Gene Therapy Can Restore Meaningful Hearing Function, Animal Study Shows

Otonomy Inc (NASDAQ: OTIC) may have hit a snag with the development of its lead ear disorder candidate Otividex. Still, the company is trumpeting an early win for a gene therapy designed to treat congen...

4 months ago - Benzinga

Otonomy and AGTC Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting

OTO-825 administration rescues hearing and cochlear damage in two preclinical models of congenital hearing loss caused by GJB2 deficiency OTO-825 administration rescues hearing and cochlear damage in tw...

4 months ago - GlobeNewsWire

Otonomy Reports First Quarter 2021 Financial Results and Provides Corporate Update

Conference call and webcast today at 4:30 p.m. ET

4 months ago - GlobeNewsWire

Otonomy to Report First Quarter 2021 Financial Results and Provide Corporate Update

SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will rep...

4 months ago - GlobeNewsWire

Otonomy and AGTC to Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting

AAV-mediated gene therapy rescues hearing and cochlear damage in two preclinical models of congenital hearing loss caused by GJB2 deficiency AAV-mediated gene therapy rescues hearing and cochlear damage...

4 months ago - GlobeNewsWire

Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

SAN DIEGO, April 19, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the closi...

5 months ago - GlobeNewsWire

Otonomy Announces Pricing of $30.1 Million Public Offering

SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the prici...

5 months ago - GlobeNewsWire

Otonomy Announces Proposed Public Offering

SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that it h...

5 months ago - GlobeNewsWire

Otonomy to Present at the Needham Virtual Healthcare Conference

SAN DIEGO, April 06, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its parti...

5 months ago - GlobeNewsWire

Otonomy Announces Presentation of OTO-313 Clinical Results at American Neurotology Society Annual Meeting

SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the prese...

5 months ago - GlobeNewsWire

Are Options Traders Betting on a Big Move in Otonomy (OTIC) Stock?

Investors need to pay close attention to Otonomy (OTIC) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

Otonomy to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that manag...

6 months ago - GlobeNewsWire

Otonomy's OTIVIDEX Fails To Separate From Placebo In Inner Ear Disorder Study

Otonomy Inc (NASDAQ: OTIC) has reported topline data from Phase 3 trial evaluating OTIVIDEX in patients with Ménière's disease. It is an inner ear disorder that causes episodes of vertigo (spinning) and...

6 months ago - Benzinga

Otonomy Announces Top-Line Results for the Phase 3 Clinical Trial of OTIVIDEX® in Patients with Ménière's Disease

SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the P...

6 months ago - GlobeNewsWire

Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting

SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced multiple p...

7 months ago - GlobeNewsWire

Otonomy Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Conference call and webcast today at 4:30 p.m. ET

7 months ago - GlobeNewsWire

Otonomy to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will re...

7 months ago - GlobeNewsWire

Otonomy And Its Efforts At Resurrecting Itself

OTIC failed a phase 3 trial and fell from $20 to $5, and hasn't recovered since despite succeeding in another phase 3. A tiebreaker third phase 3 is ongoing with data by 1Q2021.

8 months ago - Seeking Alpha